In 2025, volatility in equities was high due to Trump’s trade policies, impacting companies like Johnson & Johnson (NYSE: JNJ). The pharmaceutical giant struck a deal with the Trump administration to sell drugs at reduced prices in exchange for tariff exemptions, potentially offsetting lower prices with increased sales. Despite facing challenges like patent loss and tariffs, Johnson & Johnson’s strong performance and diversified product portfolio make it a solid investment option. With innovative capabilities and a focus on long-term growth, the company remains resilient amidst uncertainties like Medicare negotiations and lawsuits. Additionally, Johnson & Johnson is a reliable Dividend King, making it a favorable choice for income-seeking investors.

Sources:
– https://www.nasdaq.com/market-activity/stocks/jnj
– https://www.fool.com/investing/stock-market/market-sectors/healthcare/
– https://www.fool.com/terms/t/tariffs/
– https://www.fool.com/terms/e/earnings-per-share/
– https://www.fool.com/terms/m/medicare/
– https://www.fool.com/terms/p/patent-cliff/
– https://www.fool.com/investing/2025/04/20/2-recession-proof-stocks-to-buy-with-a-better-cred/
– https://www.fool.com/investing/stock-market/types-of-stocks/dividend-stocks/dividend-kings/
– https://www.fool.com/author/20111/
– https://www.fool.com/legal/fool-disclosure-policy/

Read more at Nasdaq: Is This Dividend King Stock a Buy After a Major Development?